Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat Phase 2 in Diabetic Kidney Disease
NCT04750577Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of avenciguat in diabetic kidney disease (DKD), sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04750577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750577.